Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert F Storey

Showing results (121-130 of 401) with videos related to

Pageof 41
Sort By:
Vascular Biology (Bristol, England)|December 7, 2020
The cardiac complications of COVID-19: many publications, multiple uncertaintiesAbdallah Al-Mohammad, David G Partridge, Graham Fent, et al.
Platelets|April 23, 2014
PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intactHeather M Judge, Lisa K Jennings, David J Moliterno, et al.
Cardiovascular Diabetology|December 18, 2021
A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes: role of dosing and glycaemic controlWilliam A E Parker, Rebecca Sagar, Zeyad Kurdee, et al.
British Journal of Clinical Pharmacology|November 11, 2018
Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patientsMagnus Åstrand, Carl Amilon, Daniel Röshammar, et al.
Vascular Pharmacology|April 15, 2015
Ticagrelor potentiates adenosine-induced stimulation of neutrophil chemotaxis and phagocytosisKhalaf F Alsharif, Mark R Thomas, Heather M Judge, et al.
Clinical Pharmacokinetics|April 21, 2012
Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studiesSteen E Husted, Robert F Storey, Kevin Bliden, et al.
Journal of the American College of Cardiology|September 30, 2017
Antiplatelet Agents for the Treatment and Prevention of Coronary AtherothrombosisCarlo Patrono, Joao Morais, Colin Baigent, et al.
European Heart Journal|March 25, 2021
Antithrombotic therapy in diabetes: which, when, and for how long?Ramzi A Ajjan, Noppadol Kietsiriroje, Lina Badimon, et al.
Molecular & Cellular Proteomics : MCP|December 8, 2020
A Proteomics-Based Assessment of Inflammation Signatures in EndotoxemiaSean A Burnap, Ursula Mayr, Manu Shankar-Hari, et al.
Stroke|June 27, 2013
Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials"Stefan K James, Robert F Storey, Karen S Pieper, et al.
Pageof 41

Showing results (121-130 of 401) with videos related to

Sort By:
Pageof 41
Vascular Biology (Bristol, England)|December 7, 2020
The cardiac complications of COVID-19: many publications, multiple uncertaintiesAbdallah Al-Mohammad, David G Partridge, Graham Fent, et al.
Platelets|April 23, 2014
PAR1 antagonists inhibit thrombin-induced platelet activation whilst leaving the PAR4-mediated response intactHeather M Judge, Lisa K Jennings, David J Moliterno, et al.
Cardiovascular Diabetology|December 18, 2021
A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes: role of dosing and glycaemic controlWilliam A E Parker, Rebecca Sagar, Zeyad Kurdee, et al.
British Journal of Clinical Pharmacology|November 11, 2018
Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patientsMagnus Åstrand, Carl Amilon, Daniel Röshammar, et al.
Vascular Pharmacology|April 15, 2015
Ticagrelor potentiates adenosine-induced stimulation of neutrophil chemotaxis and phagocytosisKhalaf F Alsharif, Mark R Thomas, Heather M Judge, et al.
Clinical Pharmacokinetics|April 21, 2012
Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studiesSteen E Husted, Robert F Storey, Kevin Bliden, et al.
Journal of the American College of Cardiology|September 30, 2017
Antiplatelet Agents for the Treatment and Prevention of Coronary AtherothrombosisCarlo Patrono, Joao Morais, Colin Baigent, et al.
European Heart Journal|March 25, 2021
Antithrombotic therapy in diabetes: which, when, and for how long?Ramzi A Ajjan, Noppadol Kietsiriroje, Lina Badimon, et al.
Molecular & Cellular Proteomics : MCP|December 8, 2020
A Proteomics-Based Assessment of Inflammation Signatures in EndotoxemiaSean A Burnap, Ursula Mayr, Manu Shankar-Hari, et al.
Stroke|June 27, 2013
Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials"Stefan K James, Robert F Storey, Karen S Pieper, et al.
Pageof 41